Last reviewed · How we verify
SPM 929
SPM 929 is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.
SPM 929 is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | SPM 929 |
|---|---|
| Also known as | Lacosamide |
| Sponsor | UCB Pharma |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By increasing serotonin levels, SPM 929 helps to improve mood, reduce anxiety, and alleviate symptoms of depression. This is achieved through the inhibition of the serotonin transporter, allowing more serotonin to be available for binding to its receptors in the brain.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPM 929 CI brief — competitive landscape report
- SPM 929 updates RSS · CI watch RSS
- UCB Pharma portfolio CI